Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

BACKGROUND: Children account for a substantial proportion of cases and deaths from Ebola virus disease. We aimed to assess the safety and immunogenicity of a two-dose heterologous vaccine regimen, comprising the adenovirus type 26 vector-based vaccine encoding the Ebola virus glycoprotein (Ad26.ZEBO...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lancet Infect Dis
Glavni autori: Afolabi, Muhammed O, Ishola, David, Manno, Daniela, Keshinro, Babajide, Bockstal, Viki, Rogers, Baimba, Owusu-Kyei, Kwabena, Serry-Bangura, Alimamy, Swaray, Ibrahim, Lowe, Brett, Kowuor, Dickens, Baiden, Frank, Mooney, Thomas, Smout, Elizabeth, Köhn, Brian, Otieno, Godfrey T, Jusu, Morrison, Foster, Julie, Samai, Mohamed, Deen, Gibrilla Fadlu, Larson, Heidi, Lees, Shelley, Goldstein, Neil, Gallagher, Katherine E, Gaddah, Auguste, Heerwegh, Dirk, Callendret, Benoit, Luhn, Kerstin, Robinson, Cynthia, Greenwood, Brian, Leyssen, Maarten, Douoguih, Macaya, Leigh, Bailah, Watson-Jones, Deborah
Format: Artigo
Jezik:Inglês
Izdano: 2022
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7613317/
https://ncbi.nlm.nih.gov/pubmed/34529962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(21)00128-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items